RXi Pharmaceuticals to acquire Apthera

[News]

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

More... (http://www.news-medical.net/news/20110331/RXi-Pharmaceuticals-to-acquire-Apthera.aspx)